These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33317729)

  • 1. A cross-sectional comparison of performance, neurophysiological and MRI outcomes of responders and non-responders to fampridine treatment in multiple sclerosis - An explorative study.
    Mamoei S; Jensen HB; Dalgas U; Zijdewind I; Pedersen AK; Nygaard MKE; Eskildsen SF; Stenager E
    J Clin Neurosci; 2020 Dec; 82(Pt A):179-185. PubMed ID: 33317729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis-An Explorative Study.
    Mamoei S; Jensen HB; Pedersen AK; Nygaard MKE; Eskildsen SF; Dalgas U; Stenager E
    Front Neurol; 2021; 12():758710. PubMed ID: 34764932
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
    Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in cognition, arm function and lower body function after slow-release Fampridine treatment.
    Jensen H; Ravnborg M; Mamoei S; Dalgas U; Stenager E
    Mult Scler; 2014 Dec; 20(14):1872-80. PubMed ID: 24852920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
    Jensen HB; Nielsen JL; Ravnborg M; Dalgas U; Aagaard P; Stenager E
    Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
    Jensen HB; Mamoei S; Ravnborg M; Dalgas U; Stenager E
    Mult Scler Relat Disord; 2016 May; 7():58-60. PubMed ID: 27237758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with fampridine in clinical practice: analysis of a possible marker of clinical response.
    Alvarez-Payero M; Valeiras-Muñoz C; Lion-Vázquez S; Piñeiro-Corrales G; Muñoz-García D; Midaglia L
    Int J Neurosci; 2017 Oct; 127(10):915-922. PubMed ID: 28054826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
    J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
    Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
    J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.
    Allart E; Benoit A; Blanchard-Dauphin A; Tiffreau V; Thevenon A; Zephir H; Outteryck O; Lacour A; Vermersch P
    J Neurol; 2015 Aug; 262(8):1936-45. PubMed ID: 26041616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study.
    Bakirtzis C; Konstantinopoulou E; Langdon DW; Grigoriadou E; Minti F; Nikolaidis I; Boziki MK; Tatsi T; Ioannidis P; Karapanayiotides T; Afrantou T; Hadjigeorgiou G; Grigoriadis N
    J Neurol Sci; 2018 Dec; 395():106-112. PubMed ID: 30308444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
    Ghorbanpour S; Rahimibarghani S; Rohani S; Rastkar M; Ghajarzadeh M
    Neurol Sci; 2023 Sep; 44(9):3059-3069. PubMed ID: 37055710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.